Navigation Links
New Research Shows Masimo Perfusion Index (PI) Effective in the Noninvasive Detection of Congenital Heart Defects (CHD) in Newborns
Date:11/14/2007

atal screening fails mainly in children with duct-dependent systemic circulation.

Granelli and Ostman-Smith conducted single pre- and postductal measurements of PI using the Masimo Radical SET Pulse Oximeter in a total of 10,000 healthy newborns (ranging in age from 1 hour to five days) and established PI reference values of healthy babies. In establishing reference values that validate possible PI indices for normal vs. disease state in newborns, researchers were able to show that low PI values may correspond to illness.

Study results showed that combined neonatal examination and oxygen saturation screening detected only 78% of the newborns with LHOD, but when PI was added, 100% of all newborns with LHOD showed abnormalities -- indicating that PI may reflect abnormal blood flow from the heart in CHD newborns. All LHOD newborns had either pre- or postductal PI values below the interquartile cut-off value of 1.18 and five had values below a potential cut-off of 0.70, leading researchers to conclude that "PI values lower than 0.70 may indicate illness and a value less than 0.50 indicates definite underperfusion."

Study findings suggest that a combination of saturation screening cut-offs with PI value cut-offs may help improve the early detection of congenital heart defects that have duct-dependent systemic circulation. As a result, researchers concluded that PI is a "promising tool for improving the detection of critical congenital heart disease with duct-dependent systemic circulation."(1)

Joe E. Kiani, Chairman and CEO of Masimo stated, "When we introduced Masimo SET ten years ago, we knew that the improved accuracy and fidelity would allow clinicians to more tightly control the arterial oxygen levels of their patients, but it is truly remarkable to see research like this where our technology is being used to improve screening for congenital heart defects. We are all indebted to clinicians like these from Gothenburg University who are constan
'/>"/>

SOURCE Masimo Corporation
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. The Multiple Myeloma Research Consortium (MMRC) and Proteolix Initiate Phase 2 Clinical Trial Investigating Carfilzomib for the Treatment of Multiple Myeloma
2. Multiple Myeloma Research Consortium (MMRC) Partners with Novartis to Advance Phase II Study of Deacetylase Inhibitor
3. Lexicon to Present Research Results at American Chemical Society Meeting Regarding Target of LX1031 Drug Candidate
4. Researchers at Cleveland Clinic Identify Site of Dysfunction in HDL, Carrier of Good Cholesterol
5. Video: New Research Discovers Independent Brain Networks Control Human Walking
6. Quark Pharmaceuticals Extends Research Agreement with State University of New York for Proprietary siRNA Compounds for Acute Hearing Loss
7. Cleveland Clinic Researchers Identify Mechanism Behind Platelet Function and Potentially Fatal Blood Clot Formation
8. HistoRx and Radiation Therapy Oncology Group Initiate Brain Tumor Biomarker Research Partnership
9. Diabetes Research Institute Invention Promotes Growth of Stem Cells into Insulin-Producing Cells
10. Researchers Identify Virus Possibly Responsible for Declining Honeybee Population Using 454 Sequencing Technology from Roche
11. Peregrine Researchers Report Data Showing Bavituximabs Potential to Shrink Human Prostate Tumors in Model of Relapsed Disease
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/30/2015)...  Ardelyx, Inc. (NASDAQ: ARDX ), a clinical-stage ... today announced that the Company will host its inaugural ... 1:00 pm EDT in New York City ... team will present an overview of the Company,s pipeline ... Phase 2b clinical trials for the treatment of patients ...
(Date:6/30/2015)... Fla. , June 30, 2015  July 4 th ... declaration of independence, and the spirit and people behind it. ... Foundation has partnered with USA Medical ... help increase funding for programs that empower independence for our ... country, and help more people afford their prescriptions. ...
(Date:6/30/2015)... WAYNE, Pa. , June 30, 2015 ... ("Egalet"), a fully integrated specialty pharmaceutical company ... pain treatments, today announced top-line results from ... study of Egalet-002, an abuse-deterrent, extended-release, oral ... for the management of pain severe enough ...
Breaking Medicine Technology:Ardelyx to Host Inaugural R&D Investor Day in New York City on July 14, 2015 2Hope For Heroes and USA Medical Card Make a Difference for Our Nation's Heroes 2Egalet Announces Top-Line Results from Oral Human Abuse Liability Study of Egalet-002 2Egalet Announces Top-Line Results from Oral Human Abuse Liability Study of Egalet-002 3Egalet Announces Top-Line Results from Oral Human Abuse Liability Study of Egalet-002 4Egalet Announces Top-Line Results from Oral Human Abuse Liability Study of Egalet-002 5
... Targeting Pro-Inflammatory,Protein -, GAITHERSBURG, Md., April 18, ... publication of preclinical,study data demonstrating a role ... nuclear DNA-binding protein, in the pathology,of systemic ... or lupus) and rheumatoid arthritis. Data to ...
... RIDGE, N.J., April 19, 2007 /PRNewswire-FirstCall/ --,VioQuest ... focused on acquiring, developing and,commercializing targeted cancer ... VQD- 002, a direct inhibitor of Akt,activation ... tumors.,Pre-clinical data was presented in a poster ...
Cached Medicine Technology:MedImmune Publishes New Data in Nature Immunology Demonstrating The,Role HMGB1 May Play in Systemic Autoimmune Diseases 2MedImmune Publishes New Data in Nature Immunology Demonstrating The,Role HMGB1 May Play in Systemic Autoimmune Diseases 3VioQuest Pharmaceuticals Announces Data Presentation for Its Akt,Inhibitor VQD-002, at American Association for Cancer Research,Annual Meeting 2VioQuest Pharmaceuticals Announces Data Presentation for Its Akt,Inhibitor VQD-002, at American Association for Cancer Research,Annual Meeting 3VioQuest Pharmaceuticals Announces Data Presentation for Its Akt,Inhibitor VQD-002, at American Association for Cancer Research,Annual Meeting 4VioQuest Pharmaceuticals Announces Data Presentation for Its Akt,Inhibitor VQD-002, at American Association for Cancer Research,Annual Meeting 5
(Date:6/30/2015)... ... June 30, 2015 , ... In the Spring of 2015, ... in the Sierra Nevada mountains measured zero for the first time since records have ... of one of its most sustained periods of increasing drought.” , In ...
(Date:6/30/2015)... ... ... America is in a health crisis. Today, 4 out of 5 Americans will ... The answer is simple and is at the core of every disease and dysfunction—stress. ... one million patients and, for the first time ever, gives readers and followers 12 ...
(Date:6/30/2015)... (PRWEB) , ... June 30, 2015 , ... Ticket Down is a reliable source for ... Stadium in Provo, Utah. This legendary band has been packing venues for years and ... have also released more than 20 albums in their career. While Journey is known ...
(Date:6/30/2015)... (PRWEB) , ... June 30, 2015 , ... According to ... article, early humans who lived three to four hundred thousand years ago likely ... health. By examining the chemical compounds in fossilized, ancient dental plaque, researchers were able ...
(Date:6/30/2015)... ... June 30, 2015 , ... ADVOCATE, the premier ... own Debby Mann, CPC, RCC, ROCC, Coding Documentation and Education Manager, was honored ... Recognition Award for her contribution to the RBMA Coding Subcommittee. , Ms. ...
Breaking Medicine News(10 mins):Health News:RainSoil launches water-retention product as drought spreads. 2Health News:RainSoil launches water-retention product as drought spreads. 3Health News:12 Easy-To-Follow Steps to Transform Body, Mind and Spirit 2Health News:Journey Tickets at The Stadium of Fire at Lavell Edwards Stadium in Provo, Utah: Ticket Down Slashes Ticket Prices for Journey on the 4th of July in Provo 2Health News:Recent Article Detailing Research on 400,000 Year Old Dental Plaque Shows Ancestral Understanding of Healthy Eating and Basic Oral Hygiene, Says Feiz Dental 2Health News:Recent Article Detailing Research on 400,000 Year Old Dental Plaque Shows Ancestral Understanding of Healthy Eating and Basic Oral Hygiene, Says Feiz Dental 3Health News:ADVOCATE’s Debby Mann Honored With Special Recognition Award 2
... research has found that travelers who are prone to ... risk by pulling on a pair of elastic support ... the evidence that compression stockings can prevent deep vein ... condition in which blood coagulates into small clots inside ...
... outcome, when a nurse, nurses an urge to kill. ... profession, was convicted of murdering two patients // and ... General Hospital in Oxfordshire. ,The accused had injected ... caused the patients’ to stop breathing.Geen had committed these ...
... high time somebody spoke of retirement blues. A study ... retirement despondency claims three important factors that measure a ... outlook physical health and pension, in that order. Surprisingly, ... list for a happy retirement. ,The study tracked ...
... Concerns have been raised about the alarming rate of ... According to official estimates, about 6% of Australian children ... ,VicHealth, one of the important health promotion bodies of ... to curb childhood obesity. Additionally, it has pointed out ...
... who develop pre-eclampsia, which are a condition of abnormally high ... a stroke during pregnancy. // But new studies by ... and Prevention now report that pre-eclampsia is also a risk ... Brown and colleagues in Atlanta used data from the Stroke ...
... is better than Tamoxifen in preventing breast cancer in ... said that both drugs reduce the risk of cancer ... trial show that Eli Lilly and Co's Evista, known ... could prompt clinicians to replace Tamoxifen with Evista in ...
Cached Medicine News:Health News:Travel-Related Blood Clots Can Be Reduced By Using Flight Stockings 2
The CKMB method used on the Dimension clinical chemistry system is an in vitro diagnostic test intended for the quantitative determination of creatine kinase MB isoenzyme activity in serum and plasma...
For the quantitative in vitro determination of Cholesterol in serum and plasma....
The ALP method used on the Dimension clinical chemistry system is an in vitro diagnostic test intended for the quantitative determination of alkaline phosphatase activity in serum or plasma....
The Tag-It™ Cystic Fibrosis ASR reagents can be used by high complexity CLIA approved laboratories for detection of up to 70 mutations and 6 variants (polymorphisms) in the cystic fibrosis tran...
Medicine Products: